President and Chief Executive Officer
Jim brings to Neurogastrx decades of biotech industry experience, and more than 10 years in gastrointestinal drug development and commercialization with the IBS product LINZESS® at Ironwood Pharmaceuticals. Among Jim’s notable contributions are numerous LINZESS deals he closed in the US, Europe, Japan and China. Prior to joining Ironwood, Jim was Vice President, Corporate Development for Cozint Interactive, one of the first on-line market intelligence companies. Jim began his biotech career at MPM Capital, where he focused on business development transactions for emerging biotech companies. He has a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy.
Cyril De Colle, PhD
Chief Scientific Officer
Cyril, a Neurogastrx co-founder, has more than 20 years of drug development experience, having led multiple programs from IND submission to late-stage clinical development. Before Neurogastrx, Cyril led the division at Kinemed responsible for advising global and venture backed pharmaceutical companies on neuroscience drug development programs. Prior to Kinemed, he led clinical development programs targeting neurological disorders at Jazz Pharmaceuticals and served as a senior research scientist at Amgen and Roche Pharmaceuticals. These experiences led him to explore the role of the enteric nervous system in GI conditions, such as gastroparesis, the focus of our NG-101 development program. Cyril has a Master of Science in Pharmacology and a doctorate in Neuroscience from the University of Montpellier in France.
Head of Program Management
Sara has 20 years of biopharma industry experience leading IND and NDA submissions through late-stage clinical development programs. At Sunovion Pharmaceuticals, she led the NDA submission and subsequent approval of LONHALA® MAGNAIR®, a drug-device combo to treat COPD, and was as a key contributor to the label expansion of APTIOM® for treatment of epilepsy. Prior to that, she served as development lead for Ironwood Pharmaceuticals’ linaclotide partnerships in the EU, Japan, and China. Sara began her career working in molecular biology labs for companies including Archemix and Cereon Genomics. Sara received her Bachelor of Science in Biology from Stonehill College and Master of Business Administration from Babson College.
Steve Wax, M.D., PHD
Head of Clinical Research
Steve joined Neurogastrx after nearly 15 years in clinical research for Roche and EMD Serono. Steve was drawn to work in industry following a three-year fellowship at Brigham and Women’s Hospital, focused on clinical work and basic research. He first went to Roche, where he worked on rheumatoid arthritis programs, and then to EMD Serono, where he spent more than a decade working on several Phase 1 and 2 development programs for immune-related diseases. Steve received his Doctor of Medicine and Doctor of Philosophy from Mount Sinai Medical School in New York.